Published : 01 Oct 2024

---

We are very pleased to announce that we had added another Japanese client to Aagami family.

 

Client is a Japan based company specializing in Contract manufacturing of Oligonucleotide & Peptide APIs, Process and analytical development, and providing DDS solutions. 

 

They are looking for business expansion in the US and Aagami will support this strategic need.

 

Who can benefit from this Japanese Capabilities and Offering?

 

·      Companies with pipelines in early stages, such as preclinical and Phase 

·      Companies in later stages, such as Phase 2 or Phase 3

·      Big pharmaceutical companies.

 

Please note that our client manufactures oligonucleotides using conventional solid phase synthesis and do not manufacture mRNA, which is synthesized by enzymatic methods.

 

If you are interested to know more, please contact us.